Payment overview · 2025
General Payments
$313.23
15 reported records · 8 companies
Healthcare provider profile · identity verified
Derek Anthony Pride
Allopathic & Osteopathic Physicians|Family Medicine · MYRTLE BEACH, SC · NPI 1952938847
Verified facts
What the public records show
CMS Open Payments records show Derek Anthony Pride received $313.23 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.92 | 28.7% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $80.57 | 25.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.28 | 11.3% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.52 | 11.0% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $28.50 | 9.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.36 | 4.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.98 | 4.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.10 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $313.23 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $80.57 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.44 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.28 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.52 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 551 | 171 |
| Losartan Potassium | Losartan Potassium | 255 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 221 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 72 |
| Lisinopril | Lisinopril | 198 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 55 |
| Ezetimibe | Ezetimibe | 166 | 64 |
| Simvastatin | Simvastatin | 136 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 45 |
| Gabapentin | Gabapentin | 132 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 37 |
| Omeprazole | Omeprazole | 115 | 41 |
| Trazodone Hcl | Trazodone Hcl | 115 | 38 |
| Furosemide | Furosemide | 112 | 39 |
| Allopurinol | Allopurinol | 107 | 34 |
| Azelastine Hcl | Azelastine Hcl | 107 | 64 |
| Metformin Hcl | Metformin Hcl | 100 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 28 |
| Potassium Chloride | Potassium Chloride | 87 | 34 |
| Montelukast Sodium | Montelukast Sodium | 85 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 30 |
| Alprazolam | Alprazolam | 83 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 41 |
| Alendronate Sodium | Alendronate Sodium | 77 | 27 |
| Metformin Hcl Er | Metformin Hcl | 76 | 30 |
| Baclofen | Baclofen | 69 | 41 |
| Chlorthalidone | Chlorthalidone | 68 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 22 |
| Carvedilol | Carvedilol | 62 | 20 |
| Sertraline Hcl | Sertraline Hcl | 61 | 21 |
| Ozempic | Semaglutide | 57 | 11 |
| Meloxicam | Meloxicam | 54 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 30 |
| Eliquis | Apixaban | 50 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 49 | 39 |
| Famotidine | Famotidine | 49 | 19 |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 12 |
| Repatha Sureclick | Evolocumab | 48 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Spironolactone | Spironolactone | 42 | 11 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 17 |
| Atenolol | Atenolol | 37 | 13 |
| Buspirone Hcl | Buspirone Hcl | 37 | 12 |
| Prednisone | Prednisone | 36 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 17 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | 11 |
| Valsartan | Valsartan | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Temazepam | Temazepam | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 17 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Estradiol | Estradiol | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 12 |
| Fluconazole | Fluconazole | 21 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Nystatin | Nystatin | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Mupirocin | Mupirocin | 16 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $313.23 · 15 records | Novo Nordisk Inc | Bimzelx, ISTURISA, MOUNJARO, OTEZLA, Ozempic, QUTENZA, REPATHA, Tymlos, VRAYLAR, Wegovy, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error